update on compounded semaglutide (GLP-1) altRx GLP-1 Review 2026: Updated

FDA's April 30, 2026 Proposal On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances when FDA-approved versions are available

This article explores everything you need to understand about semaglutide dosing, benefits, side effects, and how it compares to other options

Unlike typical rainbow pills, this potent compound medication doesn't merely treat the symptom but targets the very core of appetite mechanisms

127129 Telomere attrition The gradual reduction of telomeres as we grow older is a significant characteristic of aging, leading to cellular senescence and impairing tissue function

Your dose may increase over time, but your monthly price remains fixed

Faster weight loss disproportionately comes from lean tissue, which protects your metabolism and helps you keep the weight off afterwards 4,5,6